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Abstract
Introduction: Acute kidney injury (AKI), which is a major complication after cardiovascular surgery, is associated
with significant morbidity and mortality. Diuretic agents are frequently used to improve urine output and to
facilitate fluid management in these patients. Mannitol, an osmotic diuretic, is used in the perioperative setting in
the belief that it exerts reno-protective properties. In a recent study on uncomplicated postcardiac-surgery patients
with normal renal function, mannitol increased glomerular filtration rate (GFR), possibly by a deswelling effect on
tubular cells. Furthermore, experimental studies have previously shown that renal ischemia causes an endothelial
cell injury and dysfunction followed by endothelial cell edema. We studied the effects of mannitol on renal blood
flow (RBF), glomerular filtration rate (GFR), renal oxygen consumption (RVO2), and extraction (RO2Ex) in early,
ischemic AKI after cardiac surgery.
Methods: Eleven patients with AKI were studied during propofol sedation and mechanical ventilation 2 to 6 days
after complicated cardiac surgery. All patients had severe heart failure treated with one (100%) or two (73%)
inotropic agents and intraaortic balloon pump (36%). Systemic hemodynamics were measured with a pulmonary
artery catheter. RBF and renal filtration fraction (FF) were measured by the renal vein thermo-dilution technique
and by renal extraction of chromium-51-ethylenediaminetetraacetic acid (51Cr-EDTA), respectively. GFR was
calculated as the product of FF and renal plasma flow RBF × (1-hematocrit). RVO2 and RO2Ex were calculated from
arterial and renal vein blood samples according to standard formulae. After control measurements, a bolus dose of
mannitol, 225 mg/kg, was given, followed by an infusion at a rate of 75 mg/kg/h for two 30-minute periods.
Results: Mannitol did not affect cardiac index or cardiac filling pressures. Mannitol increased urine flow by 61%
(P < 0.001). This was accompanied by a 12% increase in RBF (P < 0.05) and a 13% decrease in renal vascular
resistance (P < 0.05). Mannitol increased the RBF/cardiac output (CO) relation (P = 0.040). Mannitol caused no
significant changes in RO2Ext or renal FF.
Conclusions: Mannitol treatment of postoperative AKI induces a renal vasodilation and redistributes systemic
blood flow to the kidneys. Mannitol does not affect filtration fraction or renal oxygenation, suggestive of balanced
increases in perfusion/filtration and oxygen demand/supply.
* Correspondence: sven-erik.ricksten@aniv.gu.se
Department of Anaesthesiology and Intensive Care Medicine, Sahlgrenska
Academy, University of Gothenburg, Sahlgrenska University Hospital, SE-413
45 Gothenburg, Sweden
Bragadottir et al. Critical Care 2012, 16:R159
http://ccforum.com/content/16/4/R159
© 2012 Bragadottir et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Introduction
Acute kidney injury (AKI) complicates 15% to 30% of
cardiac surgeries and is associated with significant mor-
bidity and mortality [1-4]. Even minor changes in serum
creatinine are associated with increased inpatient mortal-
ity [5,6]. Impaired renal oxygen delivery, caused by
intraoperative hypotension and hemodilution-induced
anemia and postoperative low cardiac output, is consid-
ered to be the cause of postoperative AKI in this group of
patients [4,7]. The renal medulla is at the border of
hypoxia under normal conditions, due to the concentra-
tion mechanism, and therefore particularly sensitive to
ischemia [8,9].
It was recently shown that renal oxygenation (renal
oxygen supply/demand relation) is severely impaired in
patients with early AKI after complicated cardiac surgery
[10], in turn, caused by a 50% increase in renal vascular
resistance, compared with uncomplicated postcardiac-
surgery patients. From experimental studies, it has been
suggested that renal vasoconstriction in AKI is caused by
afferent arteriolar vasoconstriction mediated by the tubu-
loglomerular feedback mechanism, vasoconstrictors
(catecholamines, angiotensin II, endothelin), and outer
medullary congestion. Furthermore, it has been ascribed
to ischemic endothelial cell injury, causing an imbalance
in the production of endothelin and endothelial nitric
oxide, or to angiotensin II-induced activation of reactive
oxygen species that inactivates NO [11-13]. Finally, it has
been suggested that outer medullary hypoxia may cause
endothelial ischemic injury and cell swelling, contributing
to congestion and impaired perfusion of this region [14].
It would therefore be logical that interventions that alle-
viate this afferent arteriolar vasoconstriction would be
beneficial, as they could potentially increase RBF and
GFR.
Oliguria is a poor prognostic indicator in patients with
AKI [15,16], and diuretic agents are frequently used to
improve urine output and to facilitate fluid management
in these patients. Mannitol, an osmotic diuretic, has been
used in the belief that it exerts renoprotective properties
in patients undergoing surgery. However, results from
studies in which mannitol has been evaluated in the peri-
operative setting, for prevention or treatment of AKI, are
divergent. Although mannitol has failed to show a pro-
phylactic effect in patients undergoing abdominal aortic
or cardiac surgery [17,18], mannitol has been shown to
reduce the incidence of postoperative AKI in the setting
of renal transplantation, along with volume expansion
[19,20]. Furthermore, mannitol treatment has been
shown to increase the glomerular filtration rate (GFR) in
patients after severe trauma or surgery [21]. In addition,
our group recently showed that mannitol increases GFR
in postoperative cardiac surgery patients [22], possibly by
a deswelling effect on tubular cells.
To evaluate in more detail the potential beneficial
effects of mannitol for treatment of AKI in the perio-
perative setting, our aim was to evaluate the effects of
mannitol on GFR, renal blood flow (RBF), renal oxygen
consumption (RVO2), and the renal oxygen supply/
demand relation in patients with early, ischemic AKI
after complicated cardiac surgery. To this end, we used
the retrograde renal vein thermodilution technique and
renal extraction of 51chromium-ethylene-diaminetetraa-
cetic acid (51Cr-EDTA) for rapid bedside estimation of
RBF and GFR without the need for urine collection [23].
In the present study, we tested the null hypothesis that
mannitol, in clinically used doses, affects neither RBF
nor GFR in patients with AKI after cardiac surgery.
Materials and methods
Study population
The study protocol was approved by the Human Ethics
Committee of the University of Gothenburg. Informed
consent was obtained from the patient’s next of kin before
enrolment in the study. Between September 2007 and
October 2011, 13 patients who developed AKI after com-
plicated heart surgery were included in the study accord-
ing to these inclusion criteria: (a) cardiac surgery with
cardiopulmonary bypass; (b) normal preoperative renal
function (serum creatinine ≤105 µM); and (c) development
of AKI, stage 1 or 2, according to the Acute Kidney Injury
Network criteria, defined as a 50% to 200% postoperative
increase in serum creatinine from baseline [5]. The follow-
ing exclusion criteria were used: (a) heart transplantation,
thoracoabdominal aortic surgery, (c) aortic dissection, (d)
use of nephrotoxic drugs such as radiocontrast agents,
aminoglycoside antibiotics, or nonsteroidal antiinflamma-
tory drug (NSAID) analgesics.
In the intensive care unit (ICU), the patients were
sedated with propofol (50.1 ± 3.3 μg/kg/min), treated with
morphine or fentanyl, and mechanically ventilated to nor-
mocapnia. The hemodynamic and renal management of
the patients was at the discretion of the attending intensive
care physician. The treatment protocol included inotropic
support with milrinone and/or norepinephrine to maintain
cardiac index ≥2.1 L/min/m2, whole-body oxygen extrac-
tion ≤40%, and mean arterial pressure (MAP) at 70 to
80 mm Hg, with or without an intraaortic balloon pump.
A continuous infusion of furosemide (5 to 40 mg/h) was
used, if needed, to promote diuresis. Because all patients
were sedated, neurologic status was not included in the
sequential organ-failure assessment score (SOFA score)
[24].
Systemic hemodynamics
Arterial blood pressure was measured with a radial or
femoral arterial catheter. Systemic hemodynamics were
measured with a pulmonary artery thermodilution
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catheter (Baxter Healthcare Corporation, Irvine, CA,
USA). Measurements of thermodilution cardiac output
were performed in triplicate and indexed to body surface
area to derive the cardiac index (CI). The mean coeffi-
cient of variation for measurement of CI was 1.6%. The
pulmonary artery wedge pressure (PCWP) was measured
intermittently. Systemic vascular resistance index (SVRI),
pulmonary vascular resistance index (PVRI), and left ven-
tricular stroke volume index (SVI) were calculated
according to standard formulae. Sodium was measured
potentiometrically with a sodium electrode (ABL800
Flex; Radiometer, Bronshoj, Denmark). The sensitivity
limits of the sodium electrode are 90% to 105%.
Measurement of renal variables
An 8-Fr catheter (Webster Laboratories, Baldwin Park,
CA, USA) was introduced into the left renal vein via the
right femoral vein, under fluoroscopic guidance. The
catheter was placed in the central portion of the renal
vein, and its position was verified with venography, by
using ultra-low doses of iohexol, 5 to 15 mg I/kg
(Omnipaque 300 mg I/ml; GE Healthcare, Stockholm,
Sweden) [25]. The technique for measurement of RBF
with retrograde thermodilution has previously been
described in detail [22,23,26,27]. The total RBF was
assumed to be twice the blood flow to the left kidney.
After blood and urine blanks were taken, an intravenous
priming dose of 51Cr-EDTA (0. 6 MBq/m2 body surface
area) was given, followed by an infusion at a constant
rate, individualized to body weight and serum creatinine.
Serum 51Cr-EDTA activities from arterial and renal vein
blood were measured with a well counter (Wizard 300,
1480 Automatic Gamma Counter; Perkin Elmer LAS,
Turku, Finland). Urine was collected in 30-minute peri-
ods to measure urine flow and sodium excretion. An
indwelling Foley catheter drained the urine from the
bladder. The levels of 51Cr-EDTA were obtained from
arterial and renal vein blood at the end of each urine-
collection period.
Experimental procedure
The patients were included in the study from 2 to 6 days
after the cardiac surgery. After an equilibration period of
at least 60 minutes, two 30-minute urine-collection con-
trol periods were started, followed by the administration
of mannitol, 150 mg/ml (Mannitol; Baxter Viaflo, Baxter
Medical AB, Kista, Sweden). The patients received a
bolus dose of mannitol, 225 mg/kg, followed by a contin-
uous infusion of mannitol at a rate of 75 mg/kg/h for two
30-minute urine collection periods. Thermodilution mea-
surements of RBF, hemodynamic variables, as well as
blood and urine samples, were obtained at the end of
each urine-collection period. During the experimental
procedure, the blood pressure was kept constant, and an
isotonic crystalloid solution was continuously infused to
substitute for fluid losses due to the diuretic response.
Data calculation
RBF was measured with retrograde thermodilution of the
left renal vein. FF was measured with renal extraction of
51Cr-EDTA, (arterial-renal vein)/arterial 51Cr-EDTA con-
centration). A significant error in the calculation of renal
extraction of filtration markers, by using this formula,
may occur in situations with high diuresis and a relatively
low renal plasma flow [28]. Renal 51Cr-EDTA extraction
and RBF values were therefore corrected by taking the
urine flow into account [28]. GFR was calculated as the
product of FF and renal plasma flow (FF × RBF × (1-
hematocrit). Renal vascular resistance (RVR) was calcu-
lated from the formula RVR = (MAP-CVP)/RBF. RVO2
and renal oxygen extraction (RO2Ex) were derived from
the formulas RVO2 = RBF × (CaO2-CvO2) and RO2Ex =
(CaO2-CvO2/CaO2), respectively, where CaO2 and CvO2
are the arterial and renal vein oxygen contents. All renal
data were normalized to a body surface area of 1.73 m2.
The glomerular filtration of sodium (GFNa) was calcu-
lated from the formula GFNa = GFR × PNa, and the tubu-
lar reabsorption of sodium (TRNa) was defined as the
difference between the filtered load of sodium and the
renal sodium excretion (that is, TRNa = GFNa - (UNa ×
UV)). Fractional excretion of sodium (FENa) was defined
as (UNa × UV)/GFNa
Statistical analysis
Based on our previous study [22], we calculated that 10
patients had to be included to detect a mannitol-induced
change in GFR of 20%, at a power of 80% and at a signifi-
cance level of 0.05, with a standard deviation of 12.2 ml
(paired design). Data on renal and hemodynamic variables
from the two control periods (C1, C2), as well as the two
mannitol-treatment periods (M1, M2) were pooled. The
renal and hemodynamic effects of mannitol, compared
with control, were assessed with a paired t test. A prob-
ability level (P value) of less than 0.05 was considered to
indicate statistical significance. The data are presented as
mean ± standard error of the mean (mean ± SEM).
Results
Thirteen patients were included in the study. Two
patients were excluded from the study because of unsuc-
cessful placement of the renal vein catheter. In total, 11
patients were thus evaluated. Baseline characteristics of
the patients are presented in Table 1. Serum creatinine
had increased by 52% to 158% at the day of study. The
patients had a mean SOFA score of 9 (range, 7 to 12). All
patients were treated with norepinephrine infusion. Eight
(73%) patients were treated with milrinone, 10 (91%)
patients had furosemide infusion, and four (36%) patients
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needed an IABP (Table 2). Two (18%) patients required
continuous renal-replacement therapy, and five (45%)
patients died during their ICU stay.
Data obtained during the two control periods, C1 and
C2, did not differ in any of the measured variables.
Effects of mannitol on systemic hemodynamic variables
Mannitol induced a significant increase in SVI (4%) and
significantly decreased Hct (2%) (Table 3). Mannitol
caused no significant changes in MAP, MPAP, CI, HR,
SVRI, or PVRI and had no effects on filling pressures
(CVP, PCWP). The body temperature did not change
during the experimental procedure.
Effects of mannitol on renal variables
Mannitol induced a significant increase in RBF (12%)
and significantly decreased RVR (-13%) (Table 4 and
Figure 1). Mannitol increased the RBF/CO relation (P =
0.040). Mannitol also caused significant increases in
urine output (61%) and FENa (58%). Although mannitol
tended to increase GFR (16%, P = 0.16), sodium filtra-
tion (18%, P = 0.14), tubular sodium reabsorption (14%,
P = 0.28), and RVO2 (10%, P = 0.14), none of these
changes reached statistical significance. Mannitol
affected neither FF nor RO2Ext.
Discussion
The main findings of the present study on cardiac sur-
gery patients with postoperative early AKI were that
mannitol induced a renal vasodilatation and increased
RBF with no changes in filtration fraction or the renal
oxygen supply/demand relation, as assessed by the lack
of effect on RO2Ex.
To our knowledge, no previous studies exist on the
effects of mannitol on renal perfusion, filtration, and oxy-
genation in patients with AKI. In most animal studies, it
has been shown that mannitol increases RBF by renal
vasodilation during both normotensive [29-31] and hypo-
tensive conditions [32-34]. Data on the effects of manni-
tol on RBF in humans, however, are scarce. With the
xenon133 washout technique, Castaneda-Zuniga et al.
Table 1 Baseline characteristics
Preoperative characteristics
Gender, n (% men) 8 (73)
Age (years) 67.1 ± 1.80
BSA (m2) 2.1 ± 0.09
Preop LVEF (%) 41.4 ± 5.56
Diabetes, type 2 (%) 2 (18)
Hypertension, n (%) 7 (64)
Serum creatinine (µM) 86.3 ± 3.41
Preoperative treatment
ACE inhibitor, n (%) 8 (73)
b-Adrenergic blocker, n (%) 10 (90)
Calcium antagonists, n (%) 1 (9)
Euroscore 7.4 ± 1.39
Perioperative characteristics
Type of surgery
CABG, n (%) 3 (27)
Valve, n (%) 4 (36)
Combined, n (%) 3 (27)
Other, n (%) 1 (9)
Nonelective, n (%) 4 (36)
CPB time (minutes) 138.1 ± 13.9
Aortic cross-clamp time (minutes) 80.8 ± 11.0
ICU Higgins risk score 9.0 ± 1.46
Data are presented as mean ± SEM. ACE, angiotensin-converting enzyme; BSA,
body surface area; CABG, coronary artery bypass surgery; CPB,
cardiopulmonary bypass; ICU, intensive care unit; LVEF, left ventricular ejection
fraction; nonelective, surgery performed within 24 hours after referral; Preop,
preoperative.




















1 4 91 151 66 12 No 0.14 0.18 0
2 4 102 170 67 7 No 0.09 0 0.99
3 2 90 146 62 10 Yes 0.33 0.44 3.70
4 6 93 210 126 7 No 0.32 0.25 1.05
5 5 84 217 158 9 No 0.27 0 0.95
6 2 82 135 65 10 No 0.33 0.26 3.21
7 2 102 155 52 10 Yes 0.92 0.26 7.41
8 4 83 182 119 10 No 0.95 0.20 6.53
9 2 81 127 57 6 Yes 0.39 0.40 2.22
10 4 62 150 141 10 Yes 0.21 0.50 1.14
11 5 79 163 107 8 No 0.40 0 5.55
Mean 3.83 90.3 164 93 9.0 36% 0.39 0.31* 1.98*
SEM 0.43 3.41 8.67 11.55 0.54 0.09 0.04* 0.78*
IABP, intraaortic balloon pump; Preop, preoperative; SOFA, sequential organ-failure assessment. *Mean and SEM among treated.
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[35] studied the effects of mannitol (20%) infusion on
RBF in humans and demonstrated only a minimal
increase in RBF. With the same methods as in the pre-
sent study, Kurnik et al. [36] studied the effect of manni-
tol (15%) on RBF in patients with moderate chronic renal
failure and found that mannitol did not affect RBF.
Those results are supported by a study, recently pub-
lished by our group, demonstrating no effect of mannitol
on RBF, in postoperative uncomplicated cardiac surgery
patients with normal renal function [22].
What are the mechanisms behind the mannitol-
induced decrease in RVR in early clinical, ischemic AKI,
as demonstrated in the present study? It has been sug-
gested that the mannitol-induced renal vasodilatory
response to experimental renal ischemia is mediated
directly by increased synthesis of prostacyclin, or indir-
ectly by augmenting plasma levels of ANP because of
the plasma volume expansion [34,37]. In the present
study, plasma volume expansion with mannitol was not
large enough to cause increased cardiac filling pressures
at the time of RBF measurements. However, we cannot
rule out the possibility that mannitol bolus plus infusion
induced a transient increase in cardiac filling pressures
and distention, causing a release of natriuretic peptides.
In our previous study in postoperative uncomplicated
cardiac patients with normal renal function, by using an
identical protocol, we found that mannitol did not affect
RBF [22], suggesting that mannitol-induced plasma
volume expansion and the consequent cardiac release of
renal vasodilatory cardiac peptides is not the main
mechanism behind the renal vasodilation, as demon-
strated in the present study.
Experimental studies have shown that renal ischemia
causes endothelial cell injury and dysfunction followed
by endothelial cell edema [14]. Flores et al. [38] showed
in an animal study that ischemia-induced endothelial
Table 3 Effects of mannitol on systemic hemodynamic variables
C1 C2 M1 M2 P value
MAP (mm Hg) 76.0 ± 1.30 75.4 ± 1.43 75.3 ± 0.91 74.6 ± 1.29 0.467
CI (L/min/m2) 2.9 ± 0.20 2.9 ± 0.21 3.0 ± 0.21 3.0 ± 0.21 0.109
SVI (ml/beat/m2) 30.5 ± 2.57 31.1 ± 2.63 31.8 ± 2.68 32.2 ± 2.55 0.046
HR (beats/min) 99.5 ± 5.78 97.1 ± 4.87 96.7 ± 4.99 96.0 ± 4.77 0.190
SVRI (dynes s/cm5/m2) 1,794 ± 112 1,776 ± 138 1,738 ± 124 1,708 ± 132 0.074
PVRI (dynes s/cm5/m2) 272 ± 26.6 278 ± 26.0 269 ± 22.9 260 ± 17.0 0.573
CVP (mm Hg) 12.6 ± 1.02 13.2 ± 0.90 13.2 ± 1.07 13.0 ± 1.04 0.531
MPAP (mm Hg) 27.1 ± 2.21 27.2 ± 2.00 27.3 ± 2.16 26.9 ± 2.06 0.933
PCWP (mm Hg) 17.3 ± 2.00 17.3 ± 1.95 17.5 ± 2.09 17.4 ± 2.02 0.720
Hct 0.313 ± 0.015 0.316 ± 0.012 0.309 ± 0.012 0.309 ± 0.013 0.012
Body temperature (oC) 37.55 ± 0.23 37.58 ± 0.21 37.54 ± 0.20 37.50 ± 0.19 0.182
Data are presented as mean ± SEM. C1, first control period before mannitol infusion; C2, second control period before mannitol infusion; CI, cardiac index; CVP,
central venous pressure; Hct, hematocrit; HR, heart rate; M1, first period with mannitol infusion (150 mg/ml, infusion rate of 0.5 ml/kg/h); M2, second period with
mannitol infusion (150 mg/ml; infusion rate of 0.5 ml/kg/h); MAP, mean arterial pressure; MPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary
wedge pressure; PVRI, pulmonary vascular resistance index; SVI, stroke volume index; SVRI, systemic vascular resistance index.
Table 4 Effects of mannitol on renal variables
C1 C2 M1 M2 P value
RBF (ml/min) 472 ± 48 465 ± 44 521 ± 49 503 ± 47 0.016
RVR (mm Hg/ml/min) 0.150 ± 0.018 0.147 ± 0.015 0.132 ± 0.014 0.135 ± 0.014 0.030
GFR (ml/min) 33.8 ± 4.6 36.0 ± 5.56 41.0 ± 7.28 39.2 ± 5.69 0.156
FF 0.104 ± 0.015 0.113 ± 0.016 0.110 ± 0.016 0.103 ± 0.011 0.743
GFNa (mmol/min) 4.82 ± 0.66 5.05 ± 0.82 5.98 ± 1.08 5.61 ± 0.82 0.141
TRNa (mmol/min) 4.45 ± 0.64 4.65 ± 0.79 5.30 ± 1.04 5.00 ± 0.79 0.286
FENa 0.078 ± 0.023 0.089 ± 0.023 0.125 ± 0.025 0.117 ± 0.021 0.008
RVO2 (ml/min) 10.62 ± 1.25 11.35 ± 1.27 12.1 ± 1.48 11.5 ± 1.30 0.138
RO2Ex 0.169 ± 0.014 0.174 ± 0.014 0.172 ± 0.016 0.170 ± 0.017 0.940
Urine flow (ml/min) 3.50 ± 0.68 3.58 ± 0.58 6.01 ± 1.09 5.38 ± 0.99 0.004
RBF/CO 0.080 ± 0.009 0.080 ± 0.008 0.088 ± 0.009 0.084 ± 0.008 0.040
Data are presented as mean ± SEM. C1, first control period before mannitol infusion; C2, second control period before mannitol infusion; FENa, fractional
excretion of sodium; FF, filtration fraction; GFNa, sodium filtration; GFR, glomerular filtration rate; M1, first period with mannitol infusion (150 mg/ml, infusion rate
of 0.5 ml/kg/h); M2, second period with mannitol infusion (150 mg/ml, infusion rate of 0.5 ml/kg/h); RBF, renal blood flow; RO2Ex, renal oxygen extraction; RVR,
renal vascular resistance; RVO2, renal oxygen consumption; TRNa, sodium reabsorption.
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cell swelling can be reversed and prevented by mannitol.
They suggested that the failure of blood flow to return
to the kidney after transient ischemia, the so-called “no
reflow” phenomenon, was due to swollen endothelial
cells, and that the no-reflow could be corrected by man-
nitol. Based on those experimental studies, one could
therefore speculate that mannitol might exert its benefi-
cial effect on renal perfusion in patients with AKI by a
deswelling effect on injured endothelial cells.
Data on the effects of mannitol on the GFR are diver-
gent. In animal studies, mannitol has been shown to
decrease [39], increase [40], or to have no effect on the
GFR [29]. In hypoperfused animal kidneys, mannitol infu-
sion tends to restore the GFR toward normal levels
[32,33,41], when given both before and after the induction
of hypotension [33,41]. Flores et al. [38] suggested that
mannitol maintains the GFR in renal ischemia primarily
by an osmotic effect that reduces vascular endothelial cell
swelling, which would reduce RVR and increase RBF.
A study on healthy human volunteers showed no effect of
mannitol on GFR [42], whereas mannitol increased creati-
nine clearance in patients with severe trauma/surgery, as
shown in a study by Valdes et al. [21]. In a recent study
on uncomplicated postcardiac-surgery patients with nor-
mal renal function, by using a protocol identical to that in
the present study, we showed that mannitol induced a
20% increase in GFR and filtration fraction with no change
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Figure 1 Effects of mannitol (M1, M2) on renal vascular resistance (RVR), renal blood flow (RBF), glomerular filtration rate (GFR), and
renal filtration fraction (FF). *P < 0.05.
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effect on tubular cells, subjected to intraoperative hypoten-
sive episodes, and recruitment of functional nephrons that
are opened up by mannitol, which will increase tubular
flow and restore GFR [43]. In the present study, mannitol
tended to increase GFR (16%), but the increase in GFR did
not reach statistical significance (P = 0.16). This study was
powered to detect a 20% increase in GFR, based on our
previous study [22]. In a post hoc power analysis, we found
that the sample size would have to be increased to 30
patients to detect a 16% increase in GFR, in the present
study, at a power of 0.8. The fact that filtration fraction
was not altered with mannitol, however, suggests that
GFR increased in proportion to the increase in renal
plasma flow in the present study. If mannitol affected only
RBF, one would have expected a decrease in the filtration
fraction, which was seen in similar group of patients
receiving low-dose dopamine, which was found to increase
RBF with no effects on the GFR [44]. Thus, we suggest
that mannitol treatment in early AKI results in both vas-
cular endothelial and tubular epithelial deswelling, which
will improve both renal perfusion and filtration
Treatment of patients with AKI with mannitol did not
affect the renal oxygen supply/demand relation, as
assessed by no changes in renal oxygen extraction. Thus,
the mannitol-induced increase in RBF was matched by a
proportional increase in RVO2. It is well known that tub-
ular sodium reabsorption is a major determinant of
RVO2 in humans [45], and it was shown previously that a
close association exists between the GFR, tubular sodium
reabsorption, and RVO2 in humans [22,27,46], and any
agent that increases the GFR has the potential to increase
the RVO2 [22,27,46]. If mannitol affected only RBF in the
present study, with no increase in GFR or RVO2, one
would have expected a decrease in renal oxygen extrac-
tion, as was seen with low-dose dopamine, which
increased RBF with no effects on the GFR or the RVO2
[44].
This study has several limitations. One major limitation
is that we did not include a time-control group. One
could, therefore, argue that changes in the measured
renal or hemodynamic variables were not entirely caused
by mannitol itself, but also, to some extent, by sponta-
neous fluctuations or time-dependent effects on these
variables. Conversely, data on renal and systemic hemo-
dynamics, as well as on renal function and oxygen meta-
bolism, obtained during the two control periods, did not
differ significantly. We, therefore, believe that the effects
of mannitol on the measured renal variables in the pre-
sent study are caused by mannitol and not by sponta-
neous fluctuations or time-dependent changes of these
variables. Another limitation of this study is the relatively
small sample size, as discussed earlier. A much larger
population of patients must be studied to evaluate
whether mannitol may improve renal outcome in AKI.
The obvious advantages with the continuous renal
vein thermodilution technique are that repeated and
rapid estimations of RBF can be performed at the bed-
side at short intervals. The thermodilution technique is
validated against the gold-standard technique, which is
the urinary clearance of PAH, corrected for by renal
extraction-fraction of PAH [23]. It is neither dependent
on a steady state, nor affected by extrarenal elimination
or by changes in renal extraction. The thermodilution
technique can, hence, be used in intensive care patients
to detect dynamic changes in RBF.
Conclusions
In the present study of patients with postoperative AKI
caused by severe heart failure, requiring inotropic and
mechanical support, we showed that treatment with the
osmotic diuretic, mannitol, induces a renal vasodilation
and increases RBF with maintained filtration fraction
and renal oxygenation.
Key messages
Mannitol in the treatment of postoperative ischemic
AKI
• causes renal vasodilation with a 12% increase in
renal blood flow
• redistributes systemic blood flow to the kidneys
• maintains renal filtration fraction (that is, causes a
balanced increase in GFR and renal plasma flow)
• maintains the renal oxygen supply/demand relation
(that is, the increase in renal blood flow was
matched by a proportional increase in renal oxygen
consumption)
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